Pathoblocker development
Scientists search for virulence factor inhibitors that target gastrointestinal pathogens such as EHEC, Salmonella and Helicobacter pylori as well as sexually transmitted bacteria like Chlamydia.
Pathoblockers are agents that specifically inhibit the pathogenic properties of microorganisms. For example, they can prevent pathogens from penetrating the intestinal wall or the mucous membranes of the vagina or uterus, or inhibit their harmful toxins. The advantage of these pathoblockers is that while conventional antibiotics damage both the pathogens and the natural bacterial community, this approach targets the pathogens, leaving the gut and vaginal microbiome intact. In addition, pathoblockers prevent the increase of antibiotic resistance.
Blockage instead of destruction
Antibiotic-resistant salmonella
DZIF scientists specifically look for inhibitors that target different pathogenic features in gastrointestinal pathogens such as EHEC, Salmonella and Helicobacter pylori, but also of sexually transmitted bacteria like Chlamydia.
Consequently, they have established a research platform that systematically examines multiple libraries in search of such substances. A potential target structure that is common to many bacteria is the so-called type III secretion system, which Salmonella, for example, use to inject destructive toxins into the host cell by means of needle-like structures.
Preventing or restricting the motility of bacteria is another avenue of attack: The therapeutic principle of motility inhibitors is based on the inhibition of the motility mediated by flagella—hair-like appendages found on various bacterial species that propel and manoeuver the cells and contribute to their pathogenicity. DZIF researchers have already been able to identify substances that could inhibit the motility of H. pylori as part of a new antibacterial therapy and thus prevent the bacterium's proliferation and pathogenic activity.
